This report is dated Feb 2020 – Bloom did had to reclassify its financial statements for 4 years with downward impact on revenue and margins.
On the other hand, UBS published a report increasing price target to $30. If anyone has access to this report or have more intelligence on Bloom, please share.
Fluence too is loss making currently but as Sahil shared can turnaround
| Subscribe To Our Free Newsletter |
